University of Glasgow
Targeted protein degradation of the Y220C-p53 mutant as a potential anti-cancer strategy
Abstract
dc:description.abstractTargeted protein degradation and Proteolysis Targeting Chimeras (PROTACs) in particular, have become an exciting new field in the drug discovery world, with the potential to target previously seen as ‘undruggable’ proteins. With many PROTACs now reaching the clinic, it is clear that these new modalities have the potential to become therapeutically successful and to overcome problems previously observed with traditional small molecule drugs. One of the most frequently mutated proteins in human cancers, p53 has been a particularly challenging drug target for many years. The work presented in this thesis provides a strategy in which to target and degrade the common Y220C p53 mutant by utilising the PROTAC degradation mechanism. In particular, PROTAC 2 was found to degrade the Y220C p53 mutant at a low micromolar concentration and hence provides insight into the potential these PROTACs hold for the future as potent degraders of target proteins.
Degree
thesis:*- Level dc:type.qualificationlevel
- MRes
- Grantor dc:publisher.institution
- University of Glasgow
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Miller, Hollie
Subjects
dc:subject × 2Rights
- Language dc:language
- en
Identifiers
dc:identifier.*- DOI dc:identifier.doi
- https://doi.org/10.5525/gla.thesis.84041